{
    "nct_id": "NCT03417297",
    "official_title": "A Pilot Open-label Clinical Trial Evaluating the ExAblate Model 4000 Type-1 Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy",
    "inclusion_criteria": "* Disabling, medically refractory epilepsy (≥2 anti-epileptic drug failures)\n* Focal onset seizures with secondary generalization; with or without primary generalized seizures.\n* ≥ 3 seizures/month on average within 3 months of enrollment.\n* Stable medication dosage for 3 months before enrollment.\n* Anterior Nucleus (AN) identifiable on MRI (structural T1 and T2 images).\n* Willing to maintain seizure diary (3 months before & 3 months after).\n* Involved care provider.\n* Written informed consent to participate.\n* Previous seizure work-up within 12 months of enrollment date to include:\n\n  1. Home EEG or Epilepsy Monitoring Unit (EMU) video EEG or intracranial EEG.\n  2. Baseline neuropsychological assessment, which includes the Wechsler Advanced Clinical Solutions - Test of Premorbid Functioning (TOPF). Participants obtaining an Intelligence Quotient (IQ) score of ≥70 on the TOPF will be included.\n  3. High-definition MRI imaging/Position emission tomography (PET) imaging\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Low seizure frequency (<3 seizures/month).\n* Indwelling vagal nerve stimulator.\n* Severe untreated neuropsychiatric disorders (untreated depression or behavioral problems).\n* Recent history of drugs or alcohol abuse.\n* Primary generalized epilepsy (Lennox Gastaut, drop attacks).\n* Post infectious epilepsy (i.e., post-herpetic).\n* Previous corpus callosotomy.\n* Significant structural brain abnormalities.\n* Unable or unwilling to maintain drug dosage for 3 months post treatment.\n* Pregnant or not practicing birth control method acceptable to the principal investigator.\n* History of claustrophobia.\n* Known allergic reaction and/or hypersensitivity to IV dye and/or IV contrasting agent(s).\n* MRI contraindicated implanted metal or medical device.\n* Uncontrolled hypertension or other comorbid conditions\n* Skull Density Ratio (SDR) <0.4.\n* IQ score of <70 on the Wechsler Advanced Clinical Solutions - Test of Premorbid Functioning (TOPF), a measure conducted as part of baseline neuropsychological assessment.",
    "miscellaneous_criteria": ""
}